Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01355796 |
|
Recruitment Status :
Completed
First Posted : May 18, 2011
Results First Posted : September 4, 2018
Last Update Posted : October 24, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Cystic fibrosis (CF) lung disease is characterized by chronic bacterial colonization and recurrent infection of the airways. Lowering the airway surface liquid (ASL) salt concentration has been shown to increase activity of salt sensitive antimicrobial peptides.
Xylitol is a 5-carbon sugar that can lower the ASL salt concentration, thus enhancing innate immunity.In this study, the investigators plan to study the safety and efficacy of 2 weeks of inhaled xylitol compared to 2 weeks of hypertonic saline in a randomized crossover design in stable subjects with cystic fibrosis
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cystic Fibrosis | Drug: Xylitol Drug: Hypertonic saline | Phase 1 Phase 2 |
Cystic fibrosis (CF) lung disease is characterized by chronic bacterial colonization and recurrent infection of the airways. Disruption of the cystic fibrosis transmembrane conductance regulator chloride channels in subjects with CF results in altered fluid and electrolyte transport across the airway epithelium thereby initiating infections.
These infections eventually destroy the lungs and contribute to significant morbidity and mortality in patients with CF. It is well known that antibacterial activity of innate immune mediators such as lysozyme and beta defensins in human airway surface liquid (ASL) is salt-sensitive; an increase in salt concentration inhibits their activity.
Conversely, their activity is increased by low ionic strength. Lowering the ASL salt concentration and increasing the ASL volume might therefore potentiate innate immunity and therefore decrease or prevent airway infections in subjects with CF.
Xylitol, a five-carbon sugar with low transepithelial permeability, which is poorly metabolized by bacteria can lower the salt concentration of both cystic fibrosis (CF) and non-CF epithelia in vitro. Xylitol is an artificial sweetener that has been successfully used in chewing gums to prevent dental caries; it has been used as an oral sugar substitute without significant adverse effects. It has also been shown to decrease the incidence of acute otitis media by 20-40%; nasal application to normal human subjects was found to decrease colonization with coagulase negative staphylococcus. The investigators found that aerosolized iso-osmolar xylitol was safe in mice, healthy volunteers and stable subjects with CF when administered over a single day. In a recent study, the investigators observed that single doses of 10% followed by 15% xylitol was well tolerated by subjects with cystic fibrosis who were stable.
In this study, the investigators plan to study the safety and efficacy of 2 weeks of inhaled xylitol compared to 2 weeks of hypertonic saline in a randomized crossover design in stable subjects with cystic fibrosis
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 30 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized Cross Over Study of Inhaled Hypertonic Xylitol Versus Hypertonic Saline in Stable Subjects With Cystic Fibrosis |
| Study Start Date : | May 2011 |
| Actual Primary Completion Date : | February 2015 |
| Actual Study Completion Date : | February 2015 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Aerosolized Hypertonic xyltiol
Aerosolized xylitol (5 ml) twice daily for 14 days
|
Drug: Xylitol
Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
Other Name: Xylo-pentane-1, 2, 3, 4, 5-pentol Drug: Hypertonic saline 4 ml of 7 % saline aerosolized twice a day for 2 weeks
Other Name: 7% NaCl |
|
Active Comparator: Hypertonic saline
Aerosolized 7% hypertonic saline (4 ml) twice daily for 14 days
|
Drug: Xylitol
Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
Other Name: Xylo-pentane-1, 2, 3, 4, 5-pentol Drug: Hypertonic saline 4 ml of 7 % saline aerosolized twice a day for 2 weeks
Other Name: 7% NaCl |
- Change in FEV1 % Predicted From Baseline [ Time Frame: Baseline and 14 days ]Change from baseline in FEV1(maximal amount of air you can forcefully exhale in one second) % predicted
- Sputum Density [ Time Frame: baseline and 14 days ]Difference from baseline in density of Pseudomonas aeruginosa colonization per gram of sputum,
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Documented diagnosis of CF (medical record evidence of 2 identified CFTR(Cystic fibrosis transmembrane conductance regulator) mutations or a positive sweat chloride test or nasal voltage difference, and 1 or more clinical findings of CF)
- Age 16 or greater
- FEV1>30% predicted
- Oxygen saturation > or equal too 90% on room air
- Clinically stable, without evidence of pulmona4ry exacerbation for at least 2 weeks prior to screening (defined as use of oral or intravenous antibiotics for cystic fibrosis exacerbation)
- Use of effective contraception in women
- Ability to provide written informed consent and assent
- Successful completion of the trial doses of study drugs
Exclusion Criteria:
- Pregnancy
- Hemoptysis more than 100 mL within the last 30 days
- Change in chronic medication within the last 30 days
- History of elevated serum creatinine (> than or equal to 2 mg/dl) within 30 days or at screening
- History of lung and other solid organ transplantation
- Wait-listed for lung or other solid organ transplant
- Known intolerance to inhaled hypertonic saline
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01355796
| United States, Illinois | |
| Northwestern University | |
| Chicago, Illinois, United States, 60611 | |
| Ann & Robert H. Lurie Children's Hospital of Chicago | |
| Chicago, Illinois, United States, 60614 | |
| Principal Investigator: | Joseph Zabner, MD | University of Iowa | |
| Study Director: | Lakshmi Durairaj, MD | University of Iowa |
| Responsible Party: | Joseph Zabner, Professor, University of Iowa |
| ClinicalTrials.gov Identifier: | NCT01355796 |
| Other Study ID Numbers: |
201209728 |
| First Posted: | May 18, 2011 Key Record Dates |
| Results First Posted: | September 4, 2018 |
| Last Update Posted: | October 24, 2018 |
| Last Verified: | September 2018 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Cystic Fibrosis Fibrosis Pathologic Processes Pancreatic Diseases Digestive System Diseases |
Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases |